Cargando…
Light-chain cardiac amyloidosis: a case report of extraordinary sustained pathological response to cyclophosphamide, bortezomib, and dexamethasone combined therapy
BACKGROUND: Heart involvement represents the most ominous prognostic factor in light-chain amyloidosis (AL), often foreclosing curative therapies such as high-dose chemotherapy followed by autologous stem cell transplantation (ASCT). Heart transplantation (HTx) may be considered before ASCT in rigor...
Autores principales: | Porcari, Aldostefano, Pagura, Linda, Rossi, Maddalena, Porrazzo, Marika, Dore, Franca, Bussani, Rossana, Merlo, Marco, Sinagra, Gianfranco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149786/ https://www.ncbi.nlm.nih.gov/pubmed/35652085 http://dx.doi.org/10.1093/ehjcr/ytac130 |
Ejemplares similares
-
A case report of isolated cardiac light chain amyloidosis without clinically overt heart failure: an under-recognized presentation
por: Nuzzi, Vincenzo, et al.
Publicado: (2023) -
Re-Definition of the Epidemiology of Cardiac Amyloidosis
por: Rossi, Maddalena, et al.
Publicado: (2022) -
Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination
por: Porcari, Aldostefano, et al.
Publicado: (2021) -
Cardiac amyloidosis: do not forget to look for it
por: Porcari, Aldostefano, et al.
Publicado: (2020) -
A Focus on Waldenström Macroglobulinemia and AL Amyloidosis
por: Lu, Rebecca, et al.
Publicado: (2022)